Sign in Register

Drug class

Antiparkinsonian Levodopa Formulations

Antiparkinsonian levodopa formulations represent a clinical grouping of dopaminergic therapies designed to deliver levodopa across various pharmacokinetic delivery systems, frequently co-formulated with peripheral decarboxylase inhibitors such as carbidopa. Read more about Antiparkinsonian Levodopa Formulations

52 drugs in this class 36 manufacturers

Advertisement

Related classes & indications

Antipsychotics, AtypicalCNS, pain & psychiatry · 296 prescription drugs Antidepressant Serotonin-Norepinephrine Reuptake Inh.(SNRIs)CNS, pain & psychiatry · 127 prescription drugs Idiopathic ParkinsonismTop indication · 357 prescription drugs

Drugs in Antiparkinsonian Levodopa Formulations

Showing 37–45 of 52 drugs

INBRIJA (levodopa)

ANTIPARKINSONIAN LEVODOPA FORMULATIONS · IDIOPATHIC PARKINSONISM
ACORDA/MERZ
Filter & compare in the drug finder → Opens the drug finder with Antiparkinsonian Levodopa Formulations preselected. Add indication or manufacturer filters there.

About Antiparkinsonian Levodopa Formulations.

Antiparkinsonian levodopa formulations represent a clinical grouping of dopaminergic therapies designed to deliver levodopa across various pharmacokinetic delivery systems, frequently co-formulated with peripheral decarboxylase inhibitors such as carbidopa.

Although not a formal standalone regulatory class name, this category encompasses immediate-release, extended-release, enteral suspension, and inhaled formulations.

These agents serve as metabolic precursors that cross the blood-brain barrier to undergo enzymatic decarboxylation into dopamine, replenishing depleted striatal dopamine levels.

Primarily indicated as cornerstone therapy for Parkinson's disease and related parkinsonian syndromes, these varied delivery systems are engineered to optimize bioavailability, relieve cardinal motor symptoms, and mitigate motor fluctuations such as end-of-dose "wearing-off" episodes.